208 related articles for article (PubMed ID: 21673063)
1. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors.
Kummar S; Raffeld M; Juwara L; Horneffer Y; Strassberger A; Allen D; Steinberg SM; Rapisarda A; Spencer SD; Figg WD; Chen X; Turkbey IB; Choyke P; Murgo AJ; Doroshow JH; Melillo G
Clin Cancer Res; 2011 Aug; 17(15):5123-31. PubMed ID: 21673063
[TBL] [Abstract][Full Text] [Related]
2. Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors.
Jeong W; Rapisarda A; Park SR; Kinders RJ; Chen A; Melillo G; Turkbey B; Steinberg SM; Choyke P; Doroshow JH; Kummar S
Cancer Chemother Pharmacol; 2014 Feb; 73(2):343-8. PubMed ID: 24292632
[TBL] [Abstract][Full Text] [Related]
3. Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha.
Puppo M; Battaglia F; Ottaviano C; Delfino S; Ribatti D; Varesio L; Bosco MC
Mol Cancer Ther; 2008 Jul; 7(7):1974-84. PubMed ID: 18645007
[TBL] [Abstract][Full Text] [Related]
4. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts.
Rapisarda A; Zalek J; Hollingshead M; Braunschweig T; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Hewitt SM; Shoemaker RH; Melillo G
Cancer Res; 2004 Oct; 64(19):6845-8. PubMed ID: 15466170
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.
Kummar S; Chen A; Ji J; Zhang Y; Reid JM; Ames M; Jia L; Weil M; Speranza G; Murgo AJ; Kinders R; Wang L; Parchment RE; Carter J; Stotler H; Rubinstein L; Hollingshead M; Melillo G; Pommier Y; Bonner W; Tomaszewski JE; Doroshow JH
Cancer Res; 2011 Sep; 71(17):5626-34. PubMed ID: 21795476
[TBL] [Abstract][Full Text] [Related]
6. HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines.
Choi YJ; Rho JK; Lee SJ; Jang WS; Lee SS; Kim CH; Lee JC
J Cancer Res Clin Oncol; 2009 Aug; 135(8):1047-53. PubMed ID: 19148680
[TBL] [Abstract][Full Text] [Related]
7. HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts.
Hartwich J; Orr WS; Ng CY; Spence Y; Morton C; Davidoff AM
J Pediatr Surg; 2013 Jan; 48(1):39-46. PubMed ID: 23331791
[TBL] [Abstract][Full Text] [Related]
8. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
Rapisarda A; Hollingshead M; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Gehrs B; Raffeld M; Kinders RJ; Parchment R; Anver MR; Shoemaker RH; Melillo G
Mol Cancer Ther; 2009 Jul; 8(7):1867-77. PubMed ID: 19584228
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of HIF-1α and CXCR4 Mitigate the Development of Radiation Necrosis in Mouse Brain.
Yang R; Duan C; Yuan L; Engelbach JA; Tsien CI; Beeman SC; Perez-Torres CJ; Ge X; Rich KM; Ackerman JJH; Garbow JR
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):1016-1025. PubMed ID: 29485043
[TBL] [Abstract][Full Text] [Related]
10. Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.
Jeong W; Park SR; Rapisarda A; Fer N; Kinders RJ; Chen A; Melillo G; Turkbey B; Steinberg SM; Choyke P; Doroshow JH; Kummar S
Invest New Drugs; 2014 Apr; 32(2):340-6. PubMed ID: 24242862
[TBL] [Abstract][Full Text] [Related]
11. Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.
Beppu K; Nakamura K; Linehan WM; Rapisarda A; Thiele CJ
Cancer Res; 2005 Jun; 65(11):4775-81. PubMed ID: 15930297
[TBL] [Abstract][Full Text] [Related]
12. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer.
Acevedo-Gadea C; Santin AD; Higgins SA; Urva S; Ratner E; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Abu-Khalaf MM
Int J Gynecol Cancer; 2014 Mar; 24(3):528-33. PubMed ID: 24557436
[TBL] [Abstract][Full Text] [Related]
14. Lenticular cytoprotection. Part 1: the role of hypoxia inducible factors-1α and -2α and vascular endothelial growth factor in lens epithelial cell survival in hypoxia.
Neelam S; Brooks MM; Cammarata PR
Mol Vis; 2013; 19():1-15. PubMed ID: 23335846
[TBL] [Abstract][Full Text] [Related]
15. Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.
Dowlati A; Levitan N; Gordon NH; Hoppel CL; Gosky DM; Remick SC; Ingalls ST; Berger SJ; Berger NA
Cancer Chemother Pharmacol; 2001; 47(2):141-8. PubMed ID: 11269740
[TBL] [Abstract][Full Text] [Related]
16. Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.
Paradziej-Łukowicz J; Skwarska A; Peszyńska-Sularz G; Brillowska-Dąbrowska A; Konopa J
Cancer Biol Ther; 2011 Oct; 12(7):586-97. PubMed ID: 21775820
[TBL] [Abstract][Full Text] [Related]
17. Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221.
Creighton-Gutteridge M; Cardellina JH; Stephen AG; Rapisarda A; Uranchimeg B; Hite K; Denny WA; Shoemaker RH; Melillo G
Clin Cancer Res; 2007 Feb; 13(3):1010-8. PubMed ID: 17289897
[TBL] [Abstract][Full Text] [Related]
18. UVC inhibits HIF-1alpha protein translation by a DNA damage- and topoisomerase I-independent pathway.
Rapisarda A; Melillo G
Oncogene; 2007 Oct; 26(48):6875-84. PubMed ID: 17496931
[TBL] [Abstract][Full Text] [Related]
19. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
[TBL] [Abstract][Full Text] [Related]
20. Current insights and future perspectives of hypoxia-inducible factor-targeted therapy in cancer.
Ajith TA
J Basic Clin Physiol Pharmacol; 2018 Dec; 30(1):11-18. PubMed ID: 30260792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
